Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4

Bo Lian,1,* Hua Wei,2,* Ruiyan Pan,3,* Jingui Sun,4 Bo Zhang,3 Jingliang Wu,1 Xiujie Li,1 Guixiang Tian1 1School of Bioscience and Technology, Weifang Medical University, Weifang 261053, People’s Republic of China; 2Department of Endocrinology, ShouGuang Peoples’ Hospital, Weifan...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lian B, Wei H, Pan R, Sun J, Zhang B, Wu J, Li X, Tian G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	liposomes anti-hepatoma co-delivery combination therapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/dbe24a1382ae4d4e884d8385cc661d6e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dbe24a1382ae4d4e884d8385cc661d6e
record_format	dspace
spelling	oai:doaj.org-article:dbe24a1382ae4d4e884d8385cc661d6e2021-12-02T13:43:44ZGalactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A41178-2013https://doaj.org/article/dbe24a1382ae4d4e884d8385cc661d6e2021-01-01T00:00:00Zhttps://www.dovepress.com/galactose-modified-liposomes-for-effective-co-delivery-of-doxorubicin--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Bo Lian,1,* Hua Wei,2,* Ruiyan Pan,3,* Jingui Sun,4 Bo Zhang,3 Jingliang Wu,1 Xiujie Li,1 Guixiang Tian1 1School of Bioscience and Technology, Weifang Medical University, Weifang 261053, People’s Republic of China; 2Department of Endocrinology, ShouGuang Peoples’ Hospital, Weifang 262700, People’s Republic of China; 3School of Pharmacy, Weifang Medical University, Weifang 261053, People’s Republic of China; 4Department of Oncology, ShouGuang Peoples’ Hospital, Weifang 262700, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xiujie Li Email lixiujie@wfmc.edu.cnGuixiang TianSchool of Bioscience and Technology, Weifang Medical University, Weifang 261053, People’s Republic of ChinaEmail gxtian2008@163.comBackground: Tumor angiogenesis plays a crucial role in tumor development, and recent efforts have been focused on combining proapoptotic and antiangiogenic activities to enhance antitumor therapy.Methods: In this study, galactose-modified liposomes (Gal-LPs) were prepared for co-delivery of doxorubicin (DOX) and combretastatin A4 phosphate (CA4P). The co-cultured system composed of BEL-7402 and human umbilical vein endothelial cells (HUVEC) cells was established to effectively evaluate in vitro anti-tumor activity through cell viability and cell migration assay. Furthermore, both in vivo bio-distribution and anti-hepatoma effect of DOX&CA4P/Gal-LPs were investigated on H22 tumor cell-bearing mice.Results: The results showed that DOX&CA4P/Gal-LPs were spherical with a mean particle size of 143 nm, and could readily be taken up by BEL-7402 cells. Compared with a mixture of free DOX and CA4P, the DOX&CA4P/Gal-LPs were more effective in inhibiting cell migration and exhibited stronger cytotoxicity against BEL-7402 cells alone or a co-cultured system. The in vitro studies showed that the co-cultured system was a more effective model to evaluate the anti-tumor activity of combination therapy. Moreover, DOX&CA4P/Gal-LPs exhibited a greater anti-hepatoma effect than other drug formulations, indicating that Gal-LPs could promote drug accumulation in the tumor region and improve the anti-tumor activity.Conclusion: Gal-LPs co-loaded with chemotherapeutic and antiangiogenic drugs are a promising strategy for anti-hepatoma therapy.Keywords: liposomes, anti-hepatoma, co-delivery, combination therapyLian BWei HPan RSun JZhang BWu JLi XTian GDove Medical Pressarticleliposomesanti-hepatomaco-deliverycombination therapyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 16, Pp 457-467 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	liposomes anti-hepatoma co-delivery combination therapy Medicine (General) R5-920
spellingShingle	liposomes anti-hepatoma co-delivery combination therapy Medicine (General) R5-920 Lian B Wei H Pan R Sun J Zhang B Wu J Li X Tian G Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4
description	Bo Lian,1,* Hua Wei,2,* Ruiyan Pan,3,* Jingui Sun,4 Bo Zhang,3 Jingliang Wu,1 Xiujie Li,1 Guixiang Tian1 1School of Bioscience and Technology, Weifang Medical University, Weifang 261053, People’s Republic of China; 2Department of Endocrinology, ShouGuang Peoples’ Hospital, Weifang 262700, People’s Republic of China; 3School of Pharmacy, Weifang Medical University, Weifang 261053, People’s Republic of China; 4Department of Oncology, ShouGuang Peoples’ Hospital, Weifang 262700, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xiujie Li Email lixiujie@wfmc.edu.cnGuixiang TianSchool of Bioscience and Technology, Weifang Medical University, Weifang 261053, People’s Republic of ChinaEmail gxtian2008@163.comBackground: Tumor angiogenesis plays a crucial role in tumor development, and recent efforts have been focused on combining proapoptotic and antiangiogenic activities to enhance antitumor therapy.Methods: In this study, galactose-modified liposomes (Gal-LPs) were prepared for co-delivery of doxorubicin (DOX) and combretastatin A4 phosphate (CA4P). The co-cultured system composed of BEL-7402 and human umbilical vein endothelial cells (HUVEC) cells was established to effectively evaluate in vitro anti-tumor activity through cell viability and cell migration assay. Furthermore, both in vivo bio-distribution and anti-hepatoma effect of DOX&CA4P/Gal-LPs were investigated on H22 tumor cell-bearing mice.Results: The results showed that DOX&CA4P/Gal-LPs were spherical with a mean particle size of 143 nm, and could readily be taken up by BEL-7402 cells. Compared with a mixture of free DOX and CA4P, the DOX&CA4P/Gal-LPs were more effective in inhibiting cell migration and exhibited stronger cytotoxicity against BEL-7402 cells alone or a co-cultured system. The in vitro studies showed that the co-cultured system was a more effective model to evaluate the anti-tumor activity of combination therapy. Moreover, DOX&CA4P/Gal-LPs exhibited a greater anti-hepatoma effect than other drug formulations, indicating that Gal-LPs could promote drug accumulation in the tumor region and improve the anti-tumor activity.Conclusion: Gal-LPs co-loaded with chemotherapeutic and antiangiogenic drugs are a promising strategy for anti-hepatoma therapy.Keywords: liposomes, anti-hepatoma, co-delivery, combination therapy
format	article
author	Lian B Wei H Pan R Sun J Zhang B Wu J Li X Tian G
author_facet	Lian B Wei H Pan R Sun J Zhang B Wu J Li X Tian G
author_sort	Lian B
title	Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4
title_short	Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4
title_full	Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4
title_fullStr	Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4
title_full_unstemmed	Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4
title_sort	galactose modified liposomes for effective co-delivery of doxorubicin and combretastatin a4
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/dbe24a1382ae4d4e884d8385cc661d6e
work_keys_str_mv	AT lianb galactosemodifiedliposomesforeffectivecodeliveryofdoxorubicinandcombretastatina4 AT weih galactosemodifiedliposomesforeffectivecodeliveryofdoxorubicinandcombretastatina4 AT panr galactosemodifiedliposomesforeffectivecodeliveryofdoxorubicinandcombretastatina4 AT sunj galactosemodifiedliposomesforeffectivecodeliveryofdoxorubicinandcombretastatina4 AT zhangb galactosemodifiedliposomesforeffectivecodeliveryofdoxorubicinandcombretastatina4 AT wuj galactosemodifiedliposomesforeffectivecodeliveryofdoxorubicinandcombretastatina4 AT lix galactosemodifiedliposomesforeffectivecodeliveryofdoxorubicinandcombretastatina4 AT tiang galactosemodifiedliposomesforeffectivecodeliveryofdoxorubicinandcombretastatina4
_version_	1718392585412673536

Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4

Ejemplares similares